JPH0959143A - Dermal preparation for external use containing 4-hydroxythiophenol - Google Patents
Dermal preparation for external use containing 4-hydroxythiophenolInfo
- Publication number
- JPH0959143A JPH0959143A JP23753195A JP23753195A JPH0959143A JP H0959143 A JPH0959143 A JP H0959143A JP 23753195 A JP23753195 A JP 23753195A JP 23753195 A JP23753195 A JP 23753195A JP H0959143 A JPH0959143 A JP H0959143A
- Authority
- JP
- Japan
- Prior art keywords
- hydroxythiophenol
- external use
- dermal preparation
- oil
- whitening
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- BXAVKNRWVKUTLY-UHFFFAOYSA-N 4-sulfanylphenol Chemical compound OC1=CC=C(S)C=C1 BXAVKNRWVKUTLY-UHFFFAOYSA-N 0.000 title claims abstract description 9
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 230000002500 effect on skin Effects 0.000 title abstract 4
- 230000002087 whitening effect Effects 0.000 abstract description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract description 7
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 abstract description 6
- 239000006210 lotion Substances 0.000 abstract description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 abstract description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 abstract description 4
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 abstract description 4
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 235000013871 bee wax Nutrition 0.000 abstract description 3
- 239000012166 beeswax Substances 0.000 abstract description 3
- 229940119170 jojoba wax Drugs 0.000 abstract description 3
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 abstract description 3
- 229960004705 kojic acid Drugs 0.000 abstract description 3
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 abstract description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 abstract description 3
- 229940032094 squalane Drugs 0.000 abstract description 3
- 229940058015 1,3-butylene glycol Drugs 0.000 abstract description 2
- 239000012190 activator Substances 0.000 abstract description 2
- 229960000271 arbutin Drugs 0.000 abstract description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 abstract description 2
- 229960000541 cetyl alcohol Drugs 0.000 abstract description 2
- 239000006071 cream Substances 0.000 abstract description 2
- 239000003906 humectant Substances 0.000 abstract description 2
- 239000007788 liquid Substances 0.000 abstract description 2
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 abstract description 2
- 239000007787 solid Substances 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- -1 Polyoxyethylene Polymers 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 3
- 102000003425 Tyrosinase Human genes 0.000 description 3
- 108060008724 Tyrosinase Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 235000011076 sorbitan monostearate Nutrition 0.000 description 3
- 239000001587 sorbitan monostearate Substances 0.000 description 3
- 229940035048 sorbitan monostearate Drugs 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000001382 Experimental Melanoma Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は美白に有効な物質に関す
る。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a substance effective for whitening.
【0002】[0002]
【従来の技術】美白作用をもった物質はすでに多くのも
のが知られている。製品化されたものにはコウジ酸、ア
ルブチンなどがある。しかし、効果が弱い等問題があっ
た。2. Description of the Related Art Many substances having a whitening effect are already known. Commercialized products include kojic acid and arbutin. However, there were problems such as a weak effect.
【0003】[0003]
【発明が解決しようとする課題】本発明の目的は、皮膚
に適用して安全であると共に、美白作用が大きい皮膚外
用剤を提供することである。SUMMARY OF THE INVENTION An object of the present invention is to provide a skin external preparation which is safe when applied to the skin and has a large whitening effect.
【0004】[0004]
【課題を解決する手段】本発明者らは、前記の課題を解
決するため、種々の物質をスクリーニングして調べ、化
粧品として利用価値のあるものを検討した。その結果、
4−ヒドロキシチオフェノールに着目し各種の実験を行
ったところ、美白作用が強いことが判明した。[Means for Solving the Problems] In order to solve the above-mentioned problems, the present inventors have screened and examined various substances and examined those which are useful as cosmetics. as a result,
When various experiments were conducted focusing on 4-hydroxythiophenol, it was found that the whitening effect was strong.
【0005】すなわち、4−ヒドロキシチオフェノール
を含む皮膚外用剤である。That is, it is a skin external preparation containing 4-hydroxythiophenol.
【0006】この物質を他の化粧品原料例えばスクワラ
ン、ホホバ油等の液状油、ミツロウ、セチルアルコール
等の固体油、各種の活性剤、グリセリン、1,3ブチレ
ングリコール等の保湿剤や各種薬剤等を添加してさまざ
まな剤形の皮膚外用剤を調整することができる。例えば
ローション、クリーム、乳液、パック等で目的に応じて
利用形態を考えればよい。This substance is used as a raw material for other cosmetics such as liquid oils such as squalane and jojoba oil, solid oils such as beeswax and cetyl alcohol, various activators, humectants such as glycerin and 1,3 butylene glycol and various chemicals. It can be added to prepare various external forms of the skin external preparation. For example, a lotion, a cream, a milky lotion, a pack, or the like may be used depending on the purpose.
【0007】[0007]
【実施例】以下に実際の利用方法である実施例を記載す
るが、本発明はこの実施例によって何ら限定されるもの
ではない。EXAMPLE An example of an actual usage will be described below, but the present invention is not limited to this example.
【0008】 実施例−1 ローション オリーブ油 0.5 4−ヒドロキシチオフェノール 0.2 ポリオキシエチレン(20E.0)ソルビタンモノステアレート 2.0 ポリオキシエチレン(60E.0)硬化ヒマシ油 2.0 エタノール 10.0 1.0%ヒアルロン酸ナトリウム水溶液 5.0 精製水 80.3Example-1 Lotion Olive oil 0.5 4-Hydroxythiophenol 0.2 Polyoxyethylene (20E.0) sorbitan monostearate 2.0 Polyoxyethylene (60E.0) hydrogenated castor oil 2.0 Ethanol 10.0 1.0% sodium hyaluronate aqueous solution 5.0 Purified water 80.3
【0009】 実施例−2 クリーム A スクワラン 20.0 オリープ油 2.0 ミンク油 1.0 ホホバ油 5.0 ミツロウ 5.0 セトステアリルアルコール 2.0 グリセリンモノステアレート 1.0 ソルビタンモノステアレート 2.0 4−ヒドロキシチオフェノール 0.1 B 精製水 48.8 ポリオキシエチレン(20E.0)ソルビタンモノステアレート 2.0 ポリオキシエチレン(60E.0)硬化ヒマシ油 1.0 グリセリン 5.0 1.0%ヒアルロン酸ナトリウム水溶液 5.0 パラオキシ安息香酸メチル 0.1 AとBをそれぞれ計量し、70℃まで加温し、BにAを
撹拌しつつ徐々に加えたのち、ゆっくり撹拌しつつ30
℃まで冷却した。Example-2 Cream A Squalane 20.0 Oleip Oil 2.0 Mink Oil 1.0 Jojoba Oil 5.0 Beeswax 5.0 Cetostearyl Alcohol 2.0 Glycerin Monostearate 1.0 Sorbitan Monostearate 2 0.0 4-Hydroxythiophenol 0.1 B Purified water 48.8 Polyoxyethylene (20E.0) sorbitan monostearate 2.0 Polyoxyethylene (60E.0) hydrogenated castor oil 1.0 Glycerin 5.01 0.0% aqueous solution of sodium hyaluronate 5.0 Methyl paraoxybenzoate 0.1 Weigh A and B respectively, warm to 70 ° C., gradually add A to B with stirring, then slowly stir 30
Cooled to ° C.
【0010】チロシナーゼ活性阻害 (試験方法)30mMリン酸ナトリウム緩衝液(pH
6.8)0.9ml、0.05%ドーパ水溶液1.0m
l、検体のジメチルスルオキシド溶液の0.1ml、精
製水0.9mlをスクリューバイアルにとり、25℃恒
温水槽中で5分以上加温した。チロシナーゼ溶液(Si
gma社製、マッシュルーム由来、914ユニット/m
l)0.1mlを加え、25℃で恒温にしたセルに入
れ、30秒後より15秒ごとに3分間475nmで吸光
度を測定した。対照として、上記試料液のかわりにジメ
チルスルオキシドを加え同様に測定した。濃度を数段階
試験を行った。 (計算式) チロシナーゼ活性阻害率(%)=(B−A)/B×10
0 但し A:試料検体の吸光度の傾き B:対照の吸光度の傾きInhibition of tyrosinase activity (Test method) 30 mM sodium phosphate buffer (pH
6.8) 0.9 ml, 0.05% dopa aqueous solution 1.0 m
l, 0.1 ml of a dimethylsulfoxide solution of a sample, and 0.9 ml of purified water were placed in a screw vial, and heated in a constant temperature water bath at 25 ° C for 5 minutes or more. Tyrosinase solution (Si
gma, mushroom-derived, 914 units / m
l) 0.1 ml was added, the mixture was placed in a cell kept at a constant temperature of 25 ° C., and the absorbance was measured at 475 nm for 15 minutes every 15 seconds after 30 seconds. As a control, dimethylsulfoxide was added instead of the above sample solution, and the measurement was performed in the same manner. The concentration was tested in several steps. (Calculation formula) Tyrosinase activity inhibition rate (%) = (BA) / B × 10
0 where A: slope of absorbance of sample B: slope of absorbance of control
【0011】[0011]
【表1】 [Table 1]
【0012】B−16メラノーマ細胞試験 検体を所定の濃度になるように、EaglesMEM培
地に加え、除菌フィルターでろ過後、牛胎児血清が10
%なるように加え、pHを7.6±0.1になるように
炭酸水素ナトリウムで調整し、シャーレに6ml分注
し、B−16メラノーマ細胞浮遊液(1×106cel
l/ml)を0.05ml加え、5%CO2、95%a
irの条件下で37℃で3日間培養した。さらに、培地
交換(上記の検体が入った10%牛胎児血清含有Eag
lesMEM培地)を行い、3日間培養した。(このと
き、細胞増殖を判定する) 細胞を剥離し、遠心分離して、細胞を集め、肉眼で白色
度の判定を行った。 白色度 ブランクと同程度 ± わずかに白色化傾向 + 明らかに白色化傾向 ++ 強い白色化傾向 +++ 細胞増殖 ブランクの80%以上 A ブランクの60〜80% B ブランクの30〜60% C ブランクの30%以下 DB-16 melanoma cell test A sample was added to Eagle's MEM medium to a predetermined concentration and filtered through a sterilization filter.
% So that the pH was adjusted to 7.6 ± 0.1 with sodium hydrogen carbonate, and 6 ml was dispensed into a petri dish, and the B-16 melanoma cell suspension (1 × 10 6 cells) was added.
1 / ml), 5% CO 2 , 95% a
The cells were cultured under ir conditions at 37 ° C for 3 days. In addition, exchange the medium (Eag containing 10% fetal bovine serum containing the above sample)
lesMEM medium) and cultured for 3 days. (At this time, cell proliferation was determined.) The cells were peeled off, centrifuged, the cells were collected, and the whiteness was visually determined. Brightness Same as blank ± Slight whitening tendency + Clear whitening tendency ++ Strong whitening tendency +++ Cell proliferation 80% or more of blank A 60-80% of blank B 30-60% of blank C 30% of blank Below D
【0013】[0013]
【表2】 [Table 2]
【0014】使用テスト 女性8名の顔面を左右に分け、一方を実施例、もう一方
を比較例として毎日、1回以上使用してもらって、3月
後、アンケートした。なお、比較例は実施例より製造例
を水にかえたものである。(比較例1,2) 判定基準は以下のようでアンケートの結果をまとめたの
が以下の表である。 実施例の方が非常によい 3 実施例の方がかなりよい 2 実施例の方がややよい 1 差がない 0 比較例の方がややよい −1 比較例の方がかなりよい −2 比較例の方が非常によい −3Use Test Eight women's faces were divided into right and left sides, one of which was used as an example and the other was used as a comparative example once or more daily, and a questionnaire was conducted after 3 months. In the comparative example, the production example was changed to water from the example. (Comparative Examples 1 and 2) The criteria are as follows, and the results of the questionnaire are summarized in the table below. Example is much better 3 Example is much better 2 Example is slightly better 1 No difference 0 Comparative example is slightly better -1 Comparative example is much better -2 Comparative example Is much better -3
【0015】 [0015]
【0016】[0016]
【効果】4−ヒドロキシチオフェノールはコウジ酸等に
比較して美白作用が強く、皮膚外用剤の有効成分として
非常に有効である。[Effect] 4-Hydroxythiophenol has a stronger whitening effect than kojic acid and the like, and is very effective as an active ingredient of a skin external preparation.
Claims (1)
膚外用剤1. An external preparation for skin containing 4-hydroxythiophenol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP23753195A JPH0959143A (en) | 1995-08-10 | 1995-08-10 | Dermal preparation for external use containing 4-hydroxythiophenol |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP23753195A JPH0959143A (en) | 1995-08-10 | 1995-08-10 | Dermal preparation for external use containing 4-hydroxythiophenol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH0959143A true JPH0959143A (en) | 1997-03-04 |
Family
ID=17016723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP23753195A Pending JPH0959143A (en) | 1995-08-10 | 1995-08-10 | Dermal preparation for external use containing 4-hydroxythiophenol |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0959143A (en) |
-
1995
- 1995-08-10 JP JP23753195A patent/JPH0959143A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100361433B1 (en) | Anti-aging cosmetic compositions containing an Extract obtained from Panax ginseng | |
| JP3558349B2 (en) | Whitening cosmetics | |
| JPH0977655A (en) | Skin preparation for external use | |
| JPH01275511A (en) | External drug for skin | |
| JPH0892053A (en) | External preparation for skin | |
| JP3611675B2 (en) | Topical skin preparation | |
| JPH0959143A (en) | Dermal preparation for external use containing 4-hydroxythiophenol | |
| JPH10212225A (en) | Wrinkle preventive | |
| JPH0925212A (en) | Skin preparation for external use | |
| JP3505003B2 (en) | External preparation | |
| JP3101090B2 (en) | External preparation for skin | |
| EP0795319A1 (en) | Compositions for fair-skin | |
| JPH04356409A (en) | Cosmetic | |
| JP4223574B2 (en) | Cosmetic composition for whitening | |
| JP3548988B2 (en) | External preparation for skin | |
| EP0503763A1 (en) | Cosmetic material | |
| JP3113009B2 (en) | Whitening cosmetics | |
| JP2003252743A (en) | Tyrosinase activity inhibitor, melanogenesis inhibitor and skin care preparation containing them | |
| JPH10109925A (en) | Beautifying and whitening cosmetic | |
| JP3452393B2 (en) | Cosmetics | |
| EP0422466A1 (en) | Endermic preparation of external application | |
| JPH10120549A (en) | Fair cosmetic | |
| JPH0597649A (en) | Cosmetic | |
| JP3354031B2 (en) | External preparation for skin | |
| JPH04124115A (en) | External preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20040218 |
|
| A131 | Notification of reasons for refusal |
Effective date: 20040302 Free format text: JAPANESE INTERMEDIATE CODE: A131 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20040511 |